top of page

CYTORA Advances Global Partnerships at the Bio Partnering J.P. Morgan Week in San Francisco

12-15 January 2026

CYTORA was proud to participate in the Bio Partnering™ at the J.P. Morgan Week held January 12–15, 2026, in San Francisco. 

 

Throughout the week, our CEO, Dr. Yona Geffen, engaged in high-level discussions with global pharmaceutical leaders and specialized investors. These sessions focused on CYTORA’s groundbreaking "off-the-shelf" human oral mucosal stem cell therapy and our strategic roadmap for U.S. commercialization via our partnership with Made Scientific and Zeo ScientifIX. The strong interest from the investment community underscores CYTORA’s position as a key innovator in the allogeneic stem cell therapeutic space.

Next
Cytora bottom logo

MENU

Cytora’s patented platform technology is based on the discovery of a novel and unique stem cell population in the human oral mucosa (hOMSC), the origin of which is the embryonic nervous system. hOMSC are endowed with properties of neural crest, neural and mesenchymal stem cells. Cytora’s products are allogeneic, off-the-shelf, easily scalable, with a very competitive cost of goods (COG). The products were found to be safe and effective in early phase clinical trials in two indications: Diabetic Foot Ulcers (DFU) and Multiple System Atrophy (MSA).

Our products have high potential for treating complicated multifactorial diseases such as chronic and neurodegenerative diseases, incurable wounds and autoimmune diseases.

CONTACT US

© 2022 Cytora. All rights reserved.

bottom of page